Literature DB >> 28864828

[Severe atypical ketoacidosis due to SGLT2-inhibitor therapy : Two case reports].

T G K Breuer1, K Kampmann1, A Wutzler2, C Steinfort3, W Uhl3, W E Schmidt1, J J Meier4.   

Abstract

Two female patients were admitted due to ketoacidosis. Serum glucose was moderately elevated. The patients exhibited abdominal and neurologic symptoms. Treatment consisted of metformin, insulin glargin and empagliflozin, as well as glimepiride, insulin detemir and empagliflozin, respectively. Treatment with intravenous fluid replacement, insulin, glucose, potassium and buffer solution led to a normalisation of pH and serum glucose levels. Our report describes two cases of atypical ketoacidosis with moderately elevated serum glucose during sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy.

Entities:  

Keywords:  Diabetes mellitus; Diabetic ketoacidosis; Fluid therapy; Insulins; Intensive care

Mesh:

Substances:

Year:  2018        PMID: 28864828     DOI: 10.1007/s00108-017-0316-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

1.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Authors:  Julio Rosenstock; Ele Ferrannini
Journal:  Diabetes Care       Date:  2015-09       Impact factor: 19.112

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes.

Authors:  S Madsbad; K G Alberti; C Binder; J M Burrin; O K Faber; T Krarup; L Regeur
Journal:  Br Med J       Date:  1979-11-17

Review 4.  [Treatment of type 2 diabetes].

Authors:  J J Meier
Journal:  Internist (Berl)       Date:  2016-02       Impact factor: 0.743

5.  Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.

Authors:  Philip A Goldberg; Mark D Siegel; Robert S Sherwin; Joshua I Halickman; Michelle Lee; Valerie A Bailey; Sandy L Lee; James D Dziura; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

6.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.

Authors:  Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-06-15       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.